SGN NANOPHARMA

SGN NanoPharma is an innovative, clinical-stage and revenue-generating developer of nanotherapeutics. The Company combines proprietary nanotechnologies with structural biology to generate superior solutions by (a) reformulating FDA approved drugs that are sub-optimal and (b) by developing novel therapies. SGN is committed to the development of nano-cannabinoid candidate products targeting topical delivery, increased bioavailability, and reduced psychotropic effects. Our aim is to safely deliver large dose therapies as an alternative to many traditional medicines such as opiates, which are currently considered over prescribed and potentially life-threatening... SGN NanoPharma Inc became operational in August 2010 with the acquisition of the MNP Technology Platform in its entirety from Novavax Inc. (Nasdaq: NVAX).

Also known as: SGN Nanopharma Inc.

Primary location: Tampa United States